This promotional website is for Healthcare Professionals only.

Prescribing information is available at the top of the page

CSL Logo
EU PI
background
Background hero

FILSPARI®▼

(sparsentan)

FOUNDATION REINVENTED WITH DUAL ACTION in IgA nephropathy1,2

Prescribing Information
icon-arrow-right

FILSPARI (sparsentan) is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g)1

Request FILSPARI materials

Please complete the form below if you would like a range of content sent to your email address to provide more information about FILSPARI in the management of IgAN.

These materials include information around the unmet need in IgAN and key results of the PROTECT phase III trial.

These materials are only available to HCPs in Germany, Austria, Switzerland and Portugal, and where FILSPARI is commercially available.

Request FILSPARI materials
icon-arrow-right

Request FILSPARI (sparsentan) materials

​If you would like a copy of the below FILSPARI materials emailed to you, please complete the form below.

  • FILSPARI Infographics – A range of infographics detailing key product information and results of the phase 3 PROTECT study​
  • FILSPARI Leavepiece – a short summary of important information about FILSPARI in IgA nephropathy​
  • Digital Bibliography – a summary of published data relating to FILSPARI and IgA nephropathy​
  • PROTECT Leavepiece – data endpoints from the PROTECT phase 3 trial
*All fields must be completed before submitting this form
Privacy Policy Terms & Conditions

Thank you!

The form was submitted successfully. You should receive an email with the requested materials attached no later than the 10th June.

Return to home page
Go home

Switch to and start FILSPARI now for sustained proteinuria reduction and to preserve kidney function1–3

Deara

FIRST AND ONLY DEARA1,4,5

FIRST AND ONLY

DEARA1,4,5

FILSPARI is the first and only DEARA, a non-immunosuppressive IgAN therapy to target both ET-1 and ANG II in a single molecule1,4,5*

Proteinuria reduction icon

SUPERIOR SUSTAINED PROTEINURIA REDUCTION2,3

Achieved rapid, superior, and sustained proteinuria reduction vs maximum-labeled dose irbesartan2,3†

Kidney function

PRESERVED KIDNEY FUNCTION2

Significantly slows the rate of eGFR decline vs maximum-labeled dose irbesartan2‡

Pill icon

ONE PILL, ONCE DAILY1

FILSPARI is suitable for continuous use,§ and has a favorable benefit-risk profile1,2,6

References & footnotes

icon expand accordion

Footnotes

*FILSPARI inhibits activation of both ETAR and AT1R, thereby reducing proteinuria and slowing progression of kidney disease1

†A significant reduction in UP/C was seen as early as Week 4 and maintained at Week 6, 12, 24, and 36, p<0.0001 at each week until Week 36. The improvement in proteinuria reduction was sustained through Week 1102,3

‡Chronic slope. Key secondary endpoints included chronic eGFR slope (rate of eGFR change over Week 6 to Week 110) and total eGFR slope (Day 1–Week 110) over the full double-blind treatment period. Chronic slope for FILSPARI vs maximum-labeled dose irbesartan was -2.7 vs -3.8 mL/min/1.73 m2 per year, respectively; difference, 1.1 mL/min/1.73 m2 per year; 95% CI, 0.1, 2.1; p=0.037. Total slope for FILSPARI vs maximum-labeled dose irbesartan was -2.9 vs -3.9 mL/min/1.73 m2 per year, respectively; difference, 1.0 mL/min/1.73 m2 per year; 95% CI, -0.03, 1.94; p=0.058. The absolute change in eGFR from baseline to Week 110 between treatment groups was 3.7 mL/min/1.73 m2 (95% CI; 1.5, 6.0)2

§Treatment may need to stopped or titrated differently depending on patient response. Continuation of treatment is at the physician's discretion. The efficacy and safety of FILSPARI was evaluated in the PROTECT study, where patients randomized to the FILSPARI treatment group received the drug for up to 110 weeks. In PROTECT, adverse events were well-balanced between groups, except for dizziness (15% with FILSPARI vs 6% with irbesartan) and hypotension (13% with FILSPARI vs 4% with irbesartan). Treatment-related adverse events led to treatment discontinuation in 21 (10%) of patients on FILSPARI vs 18 (9%) of patients on maximum-labeled dose irbesartan2

Abbreviations

ANG II, angiotensin II; AT1, angiotensin II type 1; AT1R, angiotensin II type 1 receptor; CI, confidence interval; DEARA, dual endothelin angiotensin receptor antagonist; eGFR, estimated glomerular filtration rate; ET-1, endothelin 1; ETA, endothelin type A; ETAR, endothelin type A receptor; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; UP/C, urine protein-to-creatinine ratio

References

  1. FILSPARI. EU SmPC. April 2025.
  2. Rovin B, et al. Lancet. 2023;402(10417):2077–90.
  3. Heerspink HJL, et al. Lancet. 2023;401(10388):1584–94.
  4. Syed YY, et al. Drugs. 2023;83(6):563–8
  5. Campbell KN, et al. Int J Nephrol Renovasc Dis. 2023;16-281-291.
  6. Fu W, et al. Renal Failure. 2025;47(1).

FILSPARI (sparsentan) is approved in the European Union, Iceland, Norway, Switzerland, and the United Kingdom. Best efforts have been undertaken to ensure compliance with the EFPIA Code and the EU SmPC. The SmPC can vary from country to country; before prescribing, always refer to the applicable local SmPC. Printed SmPC available upon request at the booth, abbreviated SmPC available at the content corner at the booth.

Pregancy icon

FILSPARI is contraindicated during pregnancy. FILSPARI treatment must only be initiated in women of childbearing potential when the absence of pregnancy has been verified. Women of childbearing potential have to use effective contraception during and up to 1 month after treatment has stopped.

▼ This medicinal product is subject to additional monitoring. This will allow identification of new safety information. This SmPC may be updated from time to time as necessary. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should also be reported to CSL Vifor at safety@viforpharma.com

Medicinal product subject to restricted medical prescription. Full prescribing information is available on request. Please read the full SmPC prior to administration. FILSPARI® is a registered trademark.

Vifor France. 100–101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042 Paris La Défense Cedex, France

Date of preparation: April 2025 | API job number: HQ-SPT-2400059

HQ-SPT-2500066 | Date of preparation: May 2025